SEA-BCMA
As of the edition of 20 October 2026, SEA-BCMA is a drug: stopped in 2023; acts on TNFRSF17.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Unknown
- Registered trials
- 2, 2 stopped early
- Disease areas
- Blood and lymph; Cancer; Heart and blood vessels; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B and 1 company on route A because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of SEA-BCMA.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product1 company is on route A because of SEA-BCMA.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TNFRSF17 | Tumor necrosis factor receptor superfamily member 17 | Q02223 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 0 | 0 | 2 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Cogent Biosciences | Lead sponsor of trials | 2018 to now |
| Pfizer | Lead sponsor of trials | 2018 to now |